Side Strategic Dealmaking
Companies advancing their programs to market often need access to global or regional infrastructure, expertise, and capital. Locust Walk executes licensing and acquisition transactions, connecting clients with the right partners globally across the U.S., Europe, Japan, and China.
Global and Regional Clinical Asset Partnering
We carefully position assets to ensure clear differentiation from the competitive landscape and alignment with unmet medical needs. Our team manages the full process, from marketing materials preparation, initiating outreach, soliciting term sheets, leading or supporting negotiations through to deal close. We leverage deep global and regional industry relationships to maximize value and accelerate outcomes.
Company Mergers and Acquisitions
Our white paper on the anatomy of an M&A (INSERT LINK) shows that more than 75% of public company acquisitions begin as global or regional licensing transactions. Locust Walk has led more than 20 company or asset sales, both public and private, many of which started as licensing discussions that evolved into acquisitions. We most often operate as the sole banker on a deal, but for larger transactions we can partner with other investment banks.
Pre-clinical and Platform Transactions
The majority of biotech dealmaking involves early-stage assets. Locust Walk has supported cutting-edge science through early partnerships and platform transactions, helping deploy technology as broadly as possible. In these deals, our team’s deep scientific acumen consistently proves essential, setting us apart from advisors who rely solely on financial expertise.
What Sets Us Apart
Due Diligence and Market Feedback: We apply rigorous diligence to every opportunity, ensuring only high-quality assets reach potential partners. Our due diligence committee operates independently from senior deal makers to provide an impartial evaluation ofeach opportunity.
Dual Track Processes: When assets are mature enough for a strategic transaction but a company wants to preserve optionality, we can parallel-track private financings alongside strategic transactions distinguishing ourselves from traditional investment banks.